Meyer Sarah, Söling Sara, Lampe David, Poppe Adriana, Bartels Raphaele, Grandt Daniel, Klaas Christoph, Dumröse Adda, Reber Katrin Christiane, Greiner Wolfgang, Ihle Peter, Meyer Ingo, Köberlein-Neu Juliane
Center for Health Economics and Health Services Research, University of Wuppertal, Wuppertal, North Rhine-Westphalia, Germany
Center for Health Economics and Health Services Research, University of Wuppertal, Wuppertal, North Rhine-Westphalia, Germany.
BMJ Open. 2025 Apr 15;15(4):e084696. doi: 10.1136/bmjopen-2024-084696.
Polypharmacy is associated with an increased risk of adverse patient outcomes across various settings, including inpatient care. To enhance the appropriateness of medication therapy management for patients during hospital stays, computerised interventions have shown promise with regard to patient safety. This study assesses whether the implementation of a clinical decision support system will optimise the process of inpatient medication therapy to prevent inappropriate medication use and thus promote patient safety.
The intervention will be evaluated in a prospective, cluster-randomised controlled trial using a stepped-wedge design. The study will be conducted in 12 hospitals across Germany over a total period of 33 months. Patients will be treated according to the group status of the hospital and receive either standard care or the or trans-sectoral optimisation of patient safety intervention. The primary outcome is the combined endpoint of all-cause mortality and all-cause hospitalisation. Secondary endpoints are, for example, inappropriate prescriptions, utilisation of different health services, cost-effectiveness, as well as patient-reported outcome measures. Parameters describing the attitudes of patients and healthcare professionals towards the intervention and organisational change processes will be collected as part of the process evaluation. The primary endpoint will be evaluated using hospital and outpatient claims data from participating statutory health insurances at the population level. There are multiple secondary endpoints with data linkage of primary and secondary data at study participant level. Statistical analysis will make use of (generalised) linear mixed models or generalised estimating equations, taking account of independent covariables. All data analyses of the process evaluation will be descriptive and explorative.
Data collection, storage and evaluation meet all applicable data protection regulations. The trial has been approved by the Ethics Committees of the University of Wuppertal and the Medical Association of Saarland, Germany. Results will be disseminated through workshops, peer-reviewed publications and local and international conferences.
DRKS00025485.
在包括住院治疗在内的各种医疗环境中,多重用药与患者不良结局风险增加相关。为提高患者住院期间药物治疗管理的合理性,计算机化干预措施在患者安全方面已显示出前景。本研究评估临床决策支持系统的实施是否会优化住院药物治疗过程,以防止不适当用药,从而促进患者安全。
将采用阶梯式楔形设计,在前瞻性整群随机对照试验中对干预措施进行评估。该研究将在德国的12家医院进行,为期33个月。患者将根据医院的分组状态接受治疗,接受标准护理或患者安全干预的跨部门优化。主要结局是全因死亡率和全因住院的综合终点。次要终点包括例如不适当处方、不同医疗服务的利用、成本效益以及患者报告的结局指标。作为过程评估的一部分,将收集描述患者和医护人员对干预措施及组织变革过程态度的参数。主要终点将使用参与法定健康保险的医院和门诊理赔数据在人群层面进行评估。在研究参与者层面,有多个次要终点涉及主要数据和次要数据的关联。统计分析将使用(广义)线性混合模型或广义估计方程,并考虑独立协变量。过程评估的所有数据分析将是描述性和探索性的。
数据收集、存储和评估符合所有适用的数据保护法规。该试验已获得德国伍珀塔尔大学伦理委员会和萨尔州医学协会的批准。研究结果将通过研讨会、同行评审出版物以及地方和国际会议进行传播。
DRKS00025485。